Explore more about: Diagnostics

RADx Tech program has issued contracts to help meet the ongoing needs and challenges of COVID-19 diagnostic testing.

The National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx®) Tech program is working to identify necessary elements of at-home COVID-19 diagnostic test kits that may be used independently by people with disabilities.

NIH RADx Tech Independent Test Assessment Program provides support for FDA authorization of two rapid at-home COVID-19 tests.

Artificial intelligence (AI) models that evaluate medical images have potential to speed up and improve accuracy of cancer diagnoses, but they may also be vulnerable to cyberattacks. Researchers simulated an attack that falsified mammogram images, fooling both an AI breast cancer diagnosis model and human breast imaging radiologist experts.

Awards will support innovative technologies to help improve maternal health around the world.

A team of researchers has developed a noninvasive diagnostic method that may one day replace the biopsy with a simple blood test.

The NIH RADx initiative today announced the launch of the When To Test Calculator for Individuals, a companion to the version for organizations introduced last winter. By responding to just a few prompts, the new individual impact calculator indicates whether a person should get a test—now or soon.

Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).

NIBIB-funded engineers are using deep learning to differentiate tumor more accurately from normal tissue in positron emission tomography (PET) images.

The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.